当前位置:科学网首页 > 小柯机器人 >详情
胰岛素治疗与COVID-19患者的死亡率增加相关
作者:小柯机器人 发布时间:2020/11/26 11:30:59

华中科技大学汪道文团队发现,胰岛素治疗与COVID-19患者的死亡率增加相关。这一研究成果于2020年11月23日在线发表在国际学术期刊《细胞—代谢》上。

研究人员回顾性调查了来自中国武汉市3305例队列中的689例COVID-19和2型糖尿病(T2D)患者。出乎意料的是,研究人员发现COVID-19和T2D患者的胰岛素治疗与死亡率显著增加相关[27.2%vs. 3.5%; 调整后的HR,5.38(2.75-10.54)]。进一步的分析表明,胰岛素治疗与全身炎症反应加重和重要器官损伤加重有关。因此,应谨慎对感染COVID-19的T2D患者使用胰岛素治疗。
 
据介绍,由SARS-COV2感染引起的COVID-19在重症和危重症患者中,尤其是在患有T2D合并症的患者中,可能导致多器官损伤和明显的死亡率。虽然积极控制血糖可降低死亡率,但尚不清楚包括胰岛素治疗在内的方案是否对感染COVID-19的T2D患者有益。
 
附:英文原文

Title: Insulin treatment is associated with increased mortality in patients with COVID-19

Author: Bo Yu, Chenze Li, Yang Sun, Dao Wen Wang

Issue&Volume: 2020-11-23

Abstract: COVID-19 caused by SARS-COV2 infection can lead to multi-organ injuries and significant mortality in severe and critical patients, especially among those individuals with type 2 diabetes (T2D) as a comorbidity. While attenuated mortality was observed with aggressive glucose control, it was unclear whether therapeutic regiments including insulin treatment was beneficial for patients with COVID-19 and T2D. This retrospective study investigated 689 patients with COVID-19 and T2D from a cohort of 3,305 cases from Wuhan, China. Unexpectedly, we found that insulin treatment for patients with COVID-19 and T2D was associated with a significant increase in mortality [27.2% vs. 3.5%; adjusted HR, 5.38 (2.75-10.54)]. Further analysis showed that insulin treatment was associated with enhanced systemic inflammation and aggravated injuries of vital organs. Therefore, insulin treatment for patients with COVID-19 and T2D should be used with caution.

DOI: 10.1016/j.cmet.2020.11.014

Source: https://www.cell.com/cell-metabolism/fulltext/S1550-4131(20)30647-1

期刊信息

Cell Metabolism:《细胞—代谢》,创刊于2005年。隶属于细胞出版社,最新IF:22.415
官方网址:https://www.cell.com/cell-metabolism/home
投稿链接:https://www.editorialmanager.com/cell-metabolism/default.aspx